Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lancovutide
- Development stage
- Phase 2
- Modality
- Peptides
- Administration
- Inhalation
01
Overview
Lancovutide is an investigational peptide drug developed for the treatment of cystic fibrosis. It functions by activating chloride channels, specifically calcium-dependent chloride channels (CaCC) or TMEM-16A, which are distinct from the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This mechanism aims to promote chloride efflux and rehydrate airway mucus, thereby bypassing the underlying CFTR defect in cystic fibrosis patients. Clinical trials have investigated its efficacy and safety in adolescents and adults with cystic fibrosis via inhalation.
- Other names
- 兰瑞肽
02
Targets
PE (Phosphatidylethanolamine)CaCC (Calcium-activated chloride channel protein regulator 1)ANO1 (Anoctamin-1)
Beyond the preview
Go deeper on Lancovutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lancovutide.